Register entry
Novartis Pharmaceuticals Corporation
Data as of · How to read this entry
- Registered sites
- 20
- Active NDC listings
- 199
- Labeller names
- 2
- Live patents
- 329
- Exclusivities
- 15
- Countries
- 11
- Base
- Switzerland
Authorisation
Registered operations
Analytical testing19Active ingredient (API) manufacture11Labelling8Finished drug manufacture15Packaging9particle size reduction2
Sites
Registered establishments
20| Establishment | Address | Registered for | FEI / DUNS |
|---|---|---|---|
| Novartis Pharmaceutical Manufacturing GmbHRegistrant: Novartis Pharmaceuticals Corporation | Biochemiestrasse 10, Kundl, 6250, Austria (AUT) | Analytical testing, Active ingredient (API) manufacture | 3027031635300863257 |
| Novartis Pharmaceutical Manufacturing GmbHRegistrant: Novartis Pharmaceuticals Corporation | Biochemiestrasse 10, Langkampfen, 6336, Austria (AUT) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3027031650300857102 |
| Novartis Manufacturing NVRegistrant: Novartis Pharmaceuticals Corporation | Rijksweg 14, Puurs-Sint-Amands, 2870, Belgium (BEL) | Labelling, Finished drug manufacture, Packaging | 3002037047370205429 |
| Novartis Pharma AGRegistrant: Novartis Pharmaceuticals Corporation | Lichtstrasse 35, Basel, 4056, Switzerland (CHE) | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 3002807772482347168 |
| Pharmanalytica SARegistrant: Novartis Pharmaceuticals Corporation | Via Serafino Balestra 31, Locarno, 6600, Switzerland (CHE) | Analytical testing | 3002807773487967499 |
| Novartis Pharma Schweizerhalle AGRegistrant: Novartis Pharmaceuticals Corporation | Rothausstrasse, Pratteln CH, 4133, Switzerland (CHE) | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture, particle size reduction | 3002865753481963890 |
| Novartis Pharma Stein AGRegistrant: Novartis Pharmaceuticals Corporation | Schaffhauserstrasse, Stein, CH-4332, Switzerland (CHE) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3002653483488152505 |
| Novartis Pharma Produktions GmbHRegistrant: Novartis Pharmaceuticals Corporation | Oeflinger Str. 44, Wehr, 79664, Germany (DEU) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3000978864333288046 |
| NOVARTIS PHARMA SASRegistrant: Novartis Pharmaceuticals Corporation | 8 RUE DE L INDUSTRIE, Huningue, 68330, France (FRA) | Analytical testing, Active ingredient (API) manufacture | 3004864869263159719 |
| NOVARTIS FARMA SPARegistrant: Novartis Pharmaceuticals Corporation | VIA PROVINCIALE SCHITI 131, Torre Annunziata, 80058, Italy (ITA) | Analytical testing, Finished drug manufacture | 3002807747434227739 |
| Novartis Pharmaceuticals S.R.L.Registrant: Novartis Pharmaceuticals Corporation | STR. LIVEZENI NR. 7A, Targu Mures, 540472, Romania (ROU) | Analytical testing, Finished drug manufacture, Packaging | 3005587283644903999 |
| Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd.Registrant: Novartis Pharmaceuticals Corporation | 8 Tuas Bay Lane, Singapore, 636986, Singapore (SGP) | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 3012958979659287981 |
| Novartis d.o.o.Registrant: Novartis Pharmaceuticals Corporation | Verovskova ulica 57, Ljubljana, 1000, Slovenia (SVN) | Analytical testing, Labelling, Finished drug manufacture, Packaging, particle size reduction | 3013358387655993221 |
| Novartis d.o.o.Registrant: Novartis Pharmaceuticals Corporation | Kolodvorska cesta 27, Menges, 1234, Slovenia (SVN) | Analytical testing, Active ingredient (API) manufacture, Finished drug manufacture | 3002807470988643878 |
| DSV Contract Logistics d.d.Registrant: Novartis Pharmaceuticals Corporation | Kidriceva cesta 56B, Skofja Loka, 4220, Slovenia (SVN) | Analytical testing | 3027330334988634456 |
| Novartis Saglik, Gida Ve Tarim Urunleri Sanayi Ve Ticaret Anonim SirketiRegistrant: Novartis Pharmaceuticals Corporation | Yenisehir Mahallesi, lhlara Vadisi Sokak No. 2, Istanbul, 34912, Turkey (TUR) | Analytical testing, Finished drug manufacture | 3004121450628123309 |
| Novartis Manufacturing LLCRegistrant: Novartis Pharmaceuticals Corporation | 1890 Rutherford Road, Suite 200, Carlsbad, California (CA) 92008, United States (USA) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3013510604048687485 |
| Novartis Manufacturing LLCRegistrant: Novartis Pharmaceuticals Corporation | 8520 Challenger Drive, Indianapolis, Indiana (IN) 46241, United States (USA) | Analytical testing, Active ingredient (API) manufacture, Labelling, Finished drug manufacture, Packaging | 3019881323119066300 |
| Novartis Manufacturing LLCRegistrant: Novartis Pharmaceuticals Corporation | 8540 Challenger Drive, Indianapolis, Indiana (IN) 46241, United States (USA) | Analytical testing, Active ingredient (API) manufacture | 3038913659119515121 |
| Novartis Pharmaceuticals Corporation | 220 E Hanover Ave, Morris Plains, New Jersey (NJ) 07950, United States (USA) | Analytical testing, Labelling, Finished drug manufacture, Packaging | 3010353512078640106 |
Catalogue
Drug listings by form and route
199199 active NDC listings: 168 human prescription drug, 29 bulk ingredient, 2 cellular therapy. By marketing category: NDA 148, BULK INGREDIENT 29, BLA 12, DRUG FOR FURTHER PROCESSING 10.
| Dosage form | NDCs |
|---|---|
| tablet, film coated | 54 |
| tablet | 27 |
| liquid | 16 |
| powder | 13 |
| capsule, extended release | 12 |
| injection, solution | 9 |
| capsule | 8 |
| tablet, for suspension | 7 |
| capsule, liquid filled | 6 |
| injection | 5 |
| kit | 5 |
| granule | 4 |
| injection, powder, lyophilized, for solution | 3 |
| injection, suspension | 3 |
| ointment | 3 |
| Route | NDCs |
|---|---|
| oral | 123 |
| intravenous | 14 |
| subcutaneous | 10 |
| ophthalmic | 8 |
| transdermal | 3 |
| intramuscular | 1 |
| intravitreal | 1 |
| Labeller name on the listing | NDCs |
|---|---|
| novartis pharmaceuticals corporation | 195 |
| novartis pharma sas | 4 |
Exclusivity
Patents and exclusivities
329| Patent | Product | Covers | Expiry |
|---|---|---|---|
| 9388134 | ENTRESTO, ENTRESTO SPRINKLEsacubitril; valsartan | use | Nov 2026 |
| 8389537*PED | TASIGNAnilotinib hydrochloride | use | Jan 2027 |
| 8415363*PED | TASIGNAnilotinib hydrochloride | use | Jan 2027 |
| 8501760*PED | TASIGNAnilotinib hydrochloride | use | Jan 2027 |
| 9388134*PED | ENTRESTOsacubitril; valsartan | use | May 2027 |
| 8809292 | LEQVIOinclisiran sodium | substance, product | May 2027 |
| 8877938 | ENTRESTO, ENTRESTO SPRINKLEsacubitril; valsartan | substance, product | May 2027 |
| 7378423 | MEKINISTtrametinib dimethyl sulfoxide | substance, product | May 2027 |
| 8293756 | TASIGNAnilotinib hydrochloride | product | Sept 2027 |
| 12084449 | TABRECTAcapmatinib hydrochloride | use | Nov 2027 |
| 8461330 | TABRECTAcapmatinib hydrochloride | substance, product | Nov 2027 |
| 8377921 | ZYKADIAceritinib | use | Nov 2027 |
| 8399450 | ZYKADIAceritinib | substance, product | Nov 2027 |
| 8877938*PED | ENTRESTOsacubitril; valsartan | use | Nov 2027 |
| 7378423*PED | MEKINISTtrametinib dimethyl sulfoxide | use | Nov 2027 |
| 10543179 | GILENYAfingolimod hydrochloride | use | Dec 2027 |
| 8222222 | LEQVIOinclisiran sodium | use | Dec 2027 |
| 7932241 | ZOMETAzoledronic acid | product | Feb 2028 |
| 8293756*PED | TASIGNAnilotinib hydrochloride | use | Mar 2028 |
| 7964592 | ZYKADIAceritinib | substance, product | Apr 2028 |
| 8324225 | KISQALI, KISQALI FEMARA CO-PACK (COPACKAGED)letrozole; ribociclib succinate; ribociclib succinate | substance, product | Jun 2028 |
| 9006224 | AFINITOReverolimus | use | Jul 2028 |
| 10406240 | PLUVICTOlutetium lu-177 vipivotide tetraxetan | substance, product | Aug 2028 |
| 11318121 | PLUVICTOlutetium lu-177 vipivotide tetraxetan | substance, product | Aug 2028 |
| 11369590 | LOCAMETZgallium ga-68 gozetotide | substance, product | Aug 2028 |
| 8623819 | VANRAFIAatrasentan hydrochloride | use | Aug 2028 |
| 8163904 | TASIGNAnilotinib hydrochloride | substance, product | Aug 2028 |
| 10131907 | LEQVIOinclisiran sodium | substance, product | Aug 2028 |
| 7939519 | MAYZENTsiponimod | substance, product | Aug 2028 |
| 7973031 | RYDAPTmidostaurin | use | Oct 2028 |
| 8479730 | ARCAPTA NEOHALER, SEEBRI NEOHALER, UTIBRON NEOHALERglycopyrrolate; glycopyrrolate; indacaterol maleate; indacaterol maleate | product | Oct 2028 |
| 8182838 | SEEBRI NEOHALER, UTIBRON NEOHALERglycopyrrolate; glycopyrrolate; indacaterol maleate | product | Oct 2028 |
| 10806791 | LEQVIOinclisiran sodium | substance | Dec 2028 |
| 8828956 | LEQVIOinclisiran sodium | substance, product | Dec 2028 |
| 9370582 | LEQVIOinclisiran sodium | substance, product | Dec 2028 |
| 8324225*PED | KISQALI, KISQALI FEMARA CO-PACK (COPACKAGED)letrozole; ribociclib succinate; ribociclib succinate | use | Dec 2028 |
| 8163904*PED | TASIGNAnilotinib hydrochloride | use | Feb 2029 |
| 9144561 | IZBAtravoprost | product | Mar 2029 |
| 9233956 | TAFINLARdabrafenib mesylate | use | May 2029 |
| 8754123 | IZBAtravoprost | product | May 2029 |
| 8901123 | TABRECTAcapmatinib hydrochloride | use | May 2029 |
| 9416136 | KISQALI, KISQALI FEMARA CO-PACK (COPACKAGED)letrozole; ribociclib succinate; ribociclib succinate | use | Aug 2029 |
| 8476268 | PIQRAY, VIJOICEalpelisib | substance, product | Sept 2029 |
| 8821927 | TYKERBlapatinib ditosylate | substance, product | Sept 2029 |
| 8178582 | IZBAtravoprost | product | Oct 2029 |
| 8722735 | IZBAtravoprost | product | Oct 2029 |
| 9233956*PED | TAFINLARdabrafenib mesylate | use | Nov 2029 |
| 8962630 | KISQALI, KISQALI FEMARA CO-PACK (COPACKAGED)letrozole; ribociclib succinate; ribociclib succinate | use | Dec 2029 |
| 8106022 | LEQVIOinclisiran sodium | substance, product | Dec 2029 |
| 8613949 | TEKAMLOaliskiren hemifumarate; amlodipine besylate | product | Dec 2029 |
| 7994185 | TAFINLARdabrafenib mesylate | substance, product | Jan 2030 |
| 8415345 | TAFINLARdabrafenib mesylate | substance, product | Jan 2030 |
| 9416136*PED | KISQALI, KISQALI FEMARA CO-PACK (COPACKAGED)letrozole; ribociclib succinate; ribociclib succinate | use | Feb 2030 |
| 8685980 | KISQALI, KISQALI FEMARA CO-PACK (COPACKAGED)letrozole; ribociclib succinate; ribociclib succinate | substance, product | May 2030 |
| 8962630*PED | KISQALI, KISQALI FEMARA CO-PACK (COPACKAGED)letrozole; ribociclib succinate; ribociclib succinate | use | Jun 2030 |
| 8039479 | ZYKADIAceritinib | substance, product | Jun 2030 |
| 7994185*PED | TAFINLARdabrafenib mesylate | use | Jul 2030 |
| 8415345*PED | TAFINLARdabrafenib mesylate | use | Jul 2030 |
| 8703781 | MEKINIST, TAFINLARdabrafenib mesylate; trametinib dimethyl sulfoxide | substance, product | Oct 2030 |
| 8952018 | MEKINIST, TAFINLARdabrafenib mesylate; trametinib dimethyl sulfoxide | use | Oct 2030 |
| Product | Exclusivity | Until |
|---|---|---|
| FABHALTAIPTACOPAN HYDROCHLORIDE | ODE-524 Orphan drug | Mar 2032 |
| KISQALIRIBOCICLIB SUCCINATE | PED Paediatric | Jan 2030 |
| KISQALI FEMARA CO-PACK (COPACKAGED)LETROZOLE; RIBOCICLIB SUCCINATE | PED Paediatric | Jan 2030 |
| LEQVIOINCLISIRAN SODIUM | ODE-555 Orphan drug | Feb 2033 |
| MEKINISTTRAMETINIB DIMETHYL SULFOXIDE | PED Paediatric | Sept 2030 |
| PIQRAYALPELISIB | I-937 New indication | Jan 2027 |
| PLUVICTOLUTETIUM LU-177 VIPIVOTIDE TETRAXETAN | I-996 New indication | Jul 2029 |
| RHAPSIDOREMIBRUTINIB | NCE New chemical entity | Sept 2030 |
| SCEMBLIXASCIMINIB HYDROCHLORIDE | ODE* Orphan drug | Oct 2028 |
| SCEMBLIXASCIMINIB HYDROCHLORIDE | ODE-499 Orphan drug | Oct 2031 |
| TABRECTACAPMATINIB HYDROCHLORIDE | ODE-291 Orphan drug | May 2027 |
| TAFINLARDABRAFENIB MESYLATE | PED Paediatric | Sept 2030 |
| TASIGNANILOTINIB HYDROCHLORIDE | PED Paediatric | Mar 2029 |
| VANRAFIAATRASENTAN HYDROCHLORIDE | NCE New chemical entity | Apr 2030 |
| VIJOICEALPELISIB | ODE-396 Orphan drug | Apr 2029 |
Catalogue
Marketed products
210Showing 150 of 210.
| Brand | Generic name | Form / route | NDC |
|---|---|---|---|
| ADAKVEO | crizanlizumab | injection, intravenous | 0078-0883BLA |
| Afinitor | everolimus | tablet, oral | 0078-0566NDA |
| Afinitor | everolimus | tablet, oral | 0078-0567NDA |
| Afinitor | everolimus | tablet, oral | 0078-0594NDA |
| Afinitor | everolimus | tablet, oral | 0078-0620NDA |
| Afinitor Disperz | everolimus | tablet, for suspension, oral | 0078-0626NDA |
| Afinitor Disperz | everolimus | tablet, for suspension, oral | 0078-0627NDA |
| Afinitor Disperz | everolimus | tablet, for suspension, oral | 0078-0628NDA |
| BEOVU | brolucizumab | injection, solution, intravitreal | 0078-0827BLA |
| Betoptic S | betaxolol hydrochloride | suspension/ drops, ophthalmic | 0078-0729NDA |
| - | CANAKINUMAB | liquid | 66447-0101BULK INGREDIENT |
| COARTEM | artemether and lumefantrine | tablet, oral | 0078-0568NDA |
| COSENTYX | secukinumab | injection, subcutaneous | 0078-0639BLA |
| COSENTYX | secukinumab | injection, subcutaneous | 0078-1056BLA |
| COSENTYX | secukinumab | injection, subcutaneous | 0078-1070BLA |
| COSENTYX | secukinumab | injection, solution, concentrate, intravenous | 0078-1168BLA |
| - | Clarithromycin | pellet | 0078-1315DRUG FOR FURTHER PROCESSING |
| Desferal | deferoxamine mesylate | injection, powder, lyophilized, for solution, intramuscular, intravenous, subcutaneous | 0078-0467NDA |
| Diovan | valsartan | tablet, oral | 0078-0358NDA |
| Diovan | valsartan | tablet, oral | 0078-0359NDA |
| Diovan | valsartan | tablet, oral | 0078-0360NDA |
| Diovan | valsartan | tablet, oral | 0078-0423NDA |
| Diovan | valsartan | tablet, oral | 0078-1245NDA |
| Diovan | valsartan | tablet, oral | 0078-1252NDA |
| Diovan | valsartan | tablet, oral | 0078-1259NDA |
| Diovan HCT | valsartan and hydrochlorothiazide | tablet, film coated, oral | 0078-0314NDA |
| Diovan HCT | valsartan and hydrochlorothiazide | tablet, film coated, oral | 0078-0315NDA |
| Diovan HCT | valsartan and hydrochlorothiazide | tablet, film coated, oral | 0078-0383NDA |
| Diovan HCT | valsartan and hydrochlorothiazide | tablet, film coated, oral | 0078-0471NDA |
| Diovan HCT | valsartan and hydrochlorothiazide | tablet, film coated, oral | 0078-0472NDA |
| EGATEN | triclabendazole | tablet, oral | 0078-0937NDA |
| ENTRESTO | Sacubitril and Valsartan | tablet, film coated, oral | 0078-0659NDA |
| ENTRESTO | Sacubitril and Valsartan | tablet, film coated, oral | 0078-0696NDA |
| ENTRESTO | Sacubitril and Valsartan | tablet, film coated, oral | 0078-0777NDA |
| ENTRESTO | Sacubitril and Valsartan | pellet, oral | 0078-1231NDA |
| ENTRESTO | Sacubitril and Valsartan | pellet, oral | 0078-1238NDA |
| ENTRESTO | Sacubitril and Valsartan | tablet, film coated, oral | 0078-9659NDA |
| ENTRESTO | Sacubitril and Valsartan | tablet, film coated, oral | 0078-9777NDA |
| Exelon | rivastigmine | patch, extended release, transdermal | 0078-0501NDA |
| Exelon | rivastigmine | patch, extended release, transdermal | 0078-0502NDA |
| Exelon | rivastigmine | patch, extended release, transdermal | 0078-0503NDA |
| Exforge | amlodipine besylate and valsartan | tablet, film coated, oral | 0078-0488NDA |
| Exforge | amlodipine besylate and valsartan | tablet, film coated, oral | 0078-0489NDA |
| Exforge | amlodipine besylate and valsartan | tablet, film coated, oral | 0078-0490NDA |
| Exforge | amlodipine besylate and valsartan | tablet, film coated, oral | 0078-0491NDA |
| Exforge HCT | amlodipine valsartan and hydrochlorothiazide | tablet, film coated, oral | 0078-0559NDA |
| Exforge HCT | amlodipine valsartan and hydrochlorothiazide | tablet, film coated, oral | 0078-0560NDA |
| Exforge HCT | amlodipine valsartan and hydrochlorothiazide | tablet, film coated, oral | 0078-0561NDA |
| Exforge HCT | amlodipine valsartan and hydrochlorothiazide | tablet, film coated, oral | 0078-0562NDA |
| Exforge HCT | amlodipine valsartan and hydrochlorothiazide | tablet, film coated, oral | 0078-0563NDA |
| Exjade | deferasirox | tablet, for suspension, oral | 0078-0468NDA |
| Exjade | deferasirox | tablet, for suspension, oral | 0078-0469NDA |
| Exjade | deferasirox | tablet, for suspension, oral | 0078-0470NDA |
| FABHALTA | iptacopan | capsule, oral | 0078-1189NDA |
| Femara | letrozole | tablet, film coated, oral | 0078-0249NDA |
| Focalin XR | dexmethylphenidate hydrochloride | capsule, extended release, oral | 0078-0430NDA |
| Focalin XR | dexmethylphenidate hydrochloride | capsule, extended release, oral | 0078-0431NDA |
| Focalin XR | dexmethylphenidate hydrochloride | capsule, extended release, oral | 0078-0432NDA |
| Focalin XR | dexmethylphenidate hydrochloride | capsule, extended release, oral | 0078-0433NDA |
| Focalin XR | dexmethylphenidate hydrochloride | capsule, extended release, oral | 0078-0434NDA |
| Focalin XR | dexmethylphenidate hydrochloride | capsule, extended release, oral | 0078-0493NDA |
| Focalin XR | dexmethylphenidate hydrochloride | capsule, extended release, oral | 0078-0608NDA |
| Focalin XR | dexmethylphenidate hydrochloride | capsule, extended release, oral | 0078-0609NDA |
| Gilenya | Fingolimod hcl | capsule, oral | 0078-0607NDA |
| Gilenya | Fingolimod hcl | capsule, oral | 0078-0965NDA |
| Gleevec | imatinib mesylate | tablet, oral | 0078-0401NDA |
| Gleevec | imatinib mesylate | tablet, oral | 0078-0649NDA |
| Gleevec | imatinib mesylate | tablet, oral | 0078-1490NDA |
| HYCAMTIN | topotecan hydrochloride | injection, powder, lyophilized, for solution, intravenous | 0078-0674NDA |
| ILEVRO | nepafenac | suspension/ drops, ophthalmic | 0078-0743NDA |
| Ilaris | canakinumab | injection, solution, subcutaneous | 0078-0734BLA |
| Jadenu | deferasirox | tablet, film coated, oral | 0078-0654NDA |
| Jadenu | deferasirox | tablet, film coated, oral | 0078-0655NDA |
| Jadenu | deferasirox | tablet, film coated, oral | 0078-0656NDA |
| Jadenu | deferasirox | granule, oral | 0078-0713NDA |
| Jadenu | deferasirox | granule, oral | 0078-0720NDA |
| Jadenu | deferasirox | granule, oral | 0078-0727NDA |
| KESIMPTA | ofatumumab | injection, solution, subcutaneous | 0078-1007BLA |
| KISQALI | ribociclib | tablet, film coated, oral | 0078-0860NDA |
| KISQALI | ribociclib | tablet, film coated, oral | 0078-0867NDA |
| KISQALI | ribociclib | tablet, film coated, oral | 0078-0874NDA |
| KYMRIAH | tisagenlecleucel | injection, suspension, intravenous | 0078-0846BLA |
| KYMRIAH | tisagenlecleucel | injection, suspension, intravenous | 0078-0958BLA |
| LEQVIO | inclisiran | injection, solution, subcutaneous | 0078-1000NDA |
| LOCAMETZ | kit for the preparation of gallium Ga 68 gozetotide | injection, powder, lyophilized, for solution, intravenous | 0078-1224NDA |
| Lamprene | Clofazimine | capsule, liquid filled, oral | 0078-1049NDA |
| MAXITROL | neomycin sulfate, polymyxin b sulfate and dexamethasone | ointment, ophthalmic | 0078-0771NDA |
| MAYZENT | siponimod | tablet, film coated, oral | 0078-0979NDA |
| MAYZENT | siponimod | tablet, film coated, oral | 0078-0986NDA |
| MAYZENT | siponimod | tablet, film coated, oral | 0078-1014NDA |
| Mekinist | trametinib | tablet, film coated, oral | 0078-1105NDA |
| Mekinist | trametinib | tablet, film coated, oral | 0078-1112NDA |
| Mekinist | trametinib | powder, for solution, oral | 0078-1161NDA |
| Myfortic | mycophenolic acid | tablet, delayed release, oral | 0078-0385NDA |
| Myfortic | mycophenolic acid | tablet, delayed release, oral | 0078-0386NDA |
| Neoral | cyclosporine | capsule, liquid filled, oral | 0078-0246NDA |
| Neoral | cyclosporine | capsule, liquid filled, oral | 0078-0248NDA |
| Neoral | cyclosporine | solution, oral | 0078-0274NDA |
| PIQRAY | alpelisib | tablet, oral | 0078-0701NDA |
| PIQRAY | alpelisib | tablet, oral | 0078-0708NDA |
| PIQRAY | alpelisib | kit | 0078-0715NDA |
| PLUVICTO | lutetium Lu 177 vipivotide tetraxetan | injection, solution, intravenous | 0078-1217NDA |
| PROMACTA | eltrombopag olamine | tablet, film coated, oral | 0078-0684NDA |
| PROMACTA | eltrombopag olamine | tablet, film coated, oral | 0078-0685NDA |
| PROMACTA | eltrombopag olamine | tablet, film coated, oral | 0078-0686NDA |
| PROMACTA | eltrombopag olamine | tablet, film coated, oral | 0078-0687NDA |
| PROMACTA | eltrombopag olamine | powder, for suspension, oral | 0078-0697NDA |
| PROMACTA | eltrombopag olamine | powder, for suspension, oral | 0078-0972NDA |
| RHAPSIDO | remibrutinib | tablet, oral | 0078-1483NDA |
| RYDAPT | RYDAPT | capsule, liquid filled, oral | 0078-0698NDA |
| Ritalin LA | methylphenidate hydrochloride | capsule, extended release, oral | 0078-0370NDA |
| Ritalin LA | methylphenidate hydrochloride | capsule, extended release, oral | 0078-0371NDA |
| Ritalin LA | methylphenidate hydrochloride | capsule, extended release, oral | 0078-0372NDA |
| Ritalin LA | methylphenidate hydrochloride | capsule, extended release, oral | 0078-0424NDA |
| SCEMBLIX | asciminib | tablet, film coated, oral | 0078-1091NDA |
| SCEMBLIX | asciminib | tablet, film coated, oral | 0078-1098NDA |
| SCEMBLIX | asciminib | tablet, film coated, oral | 0078-1196NDA |
| - | SECUKINUMAB | liquid | 0078-1322BULK INGREDIENT |
| Sandimmune | cyclosporine | injection, intravenous | 0078-0109NDA |
| Sandimmune | cyclosporine | capsule, liquid filled, oral | 0078-0240NDA |
| Sandimmune | cyclosporine | capsule, liquid filled, oral | 0078-0241NDA |
| Sandostatin | octreotide acetate | injection, solution, intravenous, subcutaneous | 0078-0180NDA |
| Sandostatin | octreotide acetate | injection, solution, intravenous, subcutaneous | 0078-0181NDA |
| Sandostatin | octreotide acetate | injection, solution, intravenous, subcutaneous | 0078-0182NDA |
| Sandostatin LAR Depot | octreotide acetate | kit | 0078-0811NDA |
| Sandostatin LAR Depot | octreotide acetate | kit | 0078-0818NDA |
| Sandostatin LAR Depot | octreotide acetate | kit | 0078-0825NDA |
| Simulect | basiliximab | injection, powder, for solution, intravenous | 0078-0331BLA |
| Simulect | basiliximab | injection, powder, for solution, intravenous | 0078-0393BLA |
| - | Somatropin | injection, solution | 0078-1497DRUG FOR FURTHER PROCESSING |
| TABRECTA | capmatinib | tablet, film coated, oral | 0078-0709NDA |
| TABRECTA | capmatinib | tablet, film coated, oral | 0078-0716NDA |
| TOBREX | tobramycin | ointment, ophthalmic | 0078-0813NDA |
| TRIESENCE | triamcinolone acetonide | injection, suspension, ophthalmic | 0078-0897NDA |
| TYKERB | lapatinib | tablet, oral | 0078-0671NDA |
| Tafinlar | dabrafenib | capsule, oral | 0078-0681NDA |
| Tafinlar | dabrafenib | capsule, oral | 0078-0682NDA |
| Tafinlar | dabrafenib | tablet, for suspension, oral | 0078-1154NDA |
| Tasigna | nilotinib | capsule, oral | 0078-0526NDA |
| Tasigna | nilotinib | capsule, oral | 0078-0592NDA |
| Tasigna | nilotinib | capsule, oral | 0078-0951NDA |
| Tegretol | carbamazepine | suspension, oral | 0078-0508NDA |
| Tegretol | carbamazepine | tablet, oral | 0078-0509NDA |
| Tegretol XR | carbamazepine | tablet, extended release, oral | 0078-0510NDA |
| Tegretol XR | carbamazepine | tablet, extended release, oral | 0078-0511NDA |
| Tegretol XR | carbamazepine | tablet, extended release, oral | 0078-0512NDA |
| TobraDex | tobramycin and dexamethasone | ointment, ophthalmic | 0078-0876NDA |
| Travatan Z | travoprost | solution/ drops, ophthalmic | 0078-0946NDA |
| Trileptal | oxcarbazepine | tablet, film coated, oral | 0078-0337NDA |
| Trileptal | oxcarbazepine | suspension, oral | 0078-0357NDA |
Neighbours
Registered in the same town
12- Merck & Co., Inc.Singapore, SGP · 5 sites
- Cardinal Health 418, Inc.Indianapolis, IN · 2 sites
- Lonza Biologics IncBasel, CHE; Singapore, SGP · 2 sites
- Sigma-Aldrich CorporationCarlsbad, CA · 2 sites
- SanofiSingapore, SGP · 2 sites
- Pfizer IncPuurs-Sint-Amands, BEL; Singapore, SGP · 2 sites
- Genentech, Inc.Basel, CHE; Singapore, SGP · 2 sites
- Sandoz Industrial Products S.AKundl, AUT; Langkampfen, AUT · 2 sites
- PETNET Solutions, Inc.INDIANAPOLIS, IN
- Baxalta US Inc.Singapore, SGP
- Charles River Laboratories, Inc.Singapore, SGP
- AbbVie Inc.Singapore, SGP
Compare
Comparable companies in Switzerland
- CSL Limited5 sites · 1 NDC
- CARBOGEN AMCIS AG4 sites · 13 NDC
- Kiniksa Pharmaceuticals (UK), Ltd.3 sites · 1 NDC
- ten23 health Valais AG2 sites · 1 NDC
- Merck & Cie KmG2 sites · 0 NDC
- Rommelag CDMO Switzerland AG2 sites · 0 NDC
- Herbamed AG1 site · 173 NDC
- Ricola Ag1 site · 84 NDC
- Avyxa GmbH1 site · 29 NDC
- Bachem AG1 site · 23 NDC
Enquiry
Common questions
- Is Novartis Pharmaceuticals Corporation FDA approved?
- Novartis Pharmaceuticals Corporation holds 20 FDA-registered establishments across 11 countries. Registration puts a site on the FDA's register and open to inspection; it is not an approval of the company. Approvals attach to individual drug applications.
- Where are Novartis Pharmaceuticals Corporation's drugs manufactured?
- At registered sites in Austria, Belgium, Switzerland, Germany, France, Italy and 5 other countries. The FDA register lists Kundl; Langkampfen; Puurs-Sint-Amands; Basel; Locarno; Pratteln CH, and 13 more. Registered operations: analytical testing, active ingredient (API) manufacture, labelling, finished drug manufacture, packaging, particle size reduction.
- What drugs does Novartis Pharmaceuticals Corporation make?
- 210 products are listed under Novartis Pharmaceuticals Corporation in the openFDA NDC Directory, most often as tablet, film coated; tablet; liquid. The full breakdown by dosage form and route is above. A listing count is not a sales figure.
Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.